R-PSMA I&T, with the CAS number 2647371-60-4, is a radiolabeled compound primarily used in the field of nuclear medicine, particularly for imaging and targeted therapy of prostate cancer. It is a small molecule that selectively binds to the prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells. The compound is designed to facilitate the visualization of tumors through positron emission tomography (PET) imaging, allowing for the assessment of disease progression and treatment response. R-PSMA I&T is characterized by its high affinity for PSMA, which enhances its effectiveness in targeting cancerous tissues while minimizing effects on healthy cells. Additionally, its pharmacokinetic properties are optimized for rapid clearance from non-target tissues, improving the contrast in imaging. The compound's development represents a significant advancement in personalized medicine, enabling clinicians to tailor treatment strategies based on the specific characteristics of a patient's cancer. As with any radiopharmaceutical, safety and efficacy are paramount, and its use is typically governed by strict regulatory guidelines.

R-PSMA I＆T

2647371-60-4: R-PSMA I&T, with the CAS number 2647371-60-4, is a radiolabeled compound primarily used in the field of nuclear medicine, particularly for imaging and targeted therapy of prostate cancer. It is a small molecule that selectively binds to the prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells. The compound is designed to facilitate the visualization of tumors through positron emission tomography (PET) imaging, allowing for the assessment of disease progression and treatment response. R-PSMA I&T is characterized by its high affinity for PSMA, which enhances its effectiveness in targeting cancerous tissues while minimizing effects on healthy cells. Additionally, its pharmacokinetic properties are optimized for rapid clearance from non-target tissues, improving the contrast in imaging. The compound's development represents a significant advancement in personalized medicine, enabling clinicians to tailor treatment strategies based on the specific characteristics of a patient's cancer. As with any radiopharmaceutical, safety and efficacy are paramount, and its use is typically governed by strict regulatory guidelines.

<p>Zadavotide guraxetan (PSMAI&amp;T; PNT-2002) is an inhibitor of prostate-specific membrane antigen (PSMA) with potential antitumor activity, and it is useful for research targeting prostate cancer.</p>

CAS 2647371-60-4

R-PSMA I＆T

(R)-Zadavotide guraxetan

Ref: TM-T207302